Lineage Cell Therapeutics (LCTX) Operating Leases (2014 - 2026)

Lineage Cell Therapeutics has reported Operating Leases for 13 years, with the latest figure at $1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 48.77% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (up 48.77% YoY), and the FY2025 full-year result was $1.5 million, up 18.46% from the prior year.
• Operating Leases for Q1 2026 stood at $1.5 million, down from $1.5 million in the prior quarter.
• The five-year high for Operating Leases was $2.9 million in Q4 2022, with the low at $1.0 million in Q1 2025.
• Historically, Operating Leases has averaged $1.8 million across 5 years, with a median of $1.8 million in 2022.
• Annual changes were most pronounced in 2025 — Operating Leases sank 51.16% — and 2026, when it surged 48.77%.
• Lineage Cell Therapeutics' Operating Leases stood at $2.9 million in 2022, then sank by 30.8% to $2.0 million in 2023, then sank by 34.56% to $1.3 million in 2024, then grew by 18.46% to $1.5 million in 2025, then decreased by 1.76% to $1.5 million in 2026.
• The last three Operating Leases figures came in at $1.5 million (Q1 2026), $1.5 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.